DE60122516D1 - Phosphonatderivate eines glykopeptides - Google Patents

Phosphonatderivate eines glykopeptides

Info

Publication number
DE60122516D1
DE60122516D1 DE60122516T DE60122516T DE60122516D1 DE 60122516 D1 DE60122516 D1 DE 60122516D1 DE 60122516 T DE60122516 T DE 60122516T DE 60122516 T DE60122516 T DE 60122516T DE 60122516 D1 DE60122516 D1 DE 60122516D1
Authority
DE
Germany
Prior art keywords
glycopeptide
phosphonate derivatives
phosphonate
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60122516T
Other languages
English (en)
Other versions
DE60122516T2 (de
Inventor
R Leadbetter
S Linsell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Application granted granted Critical
Publication of DE60122516D1 publication Critical patent/DE60122516D1/de
Publication of DE60122516T2 publication Critical patent/DE60122516T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
DE60122516T 2000-06-22 2001-05-01 Phosphonatderivate eines glykopeptides Expired - Lifetime DE60122516T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21341000P 2000-06-22 2000-06-22
US213410P 2000-06-22
PCT/US2001/013998 WO2001098328A2 (en) 2000-06-22 2001-05-01 Glycopeptide phosphonate derivatives

Publications (2)

Publication Number Publication Date
DE60122516D1 true DE60122516D1 (de) 2006-10-05
DE60122516T2 DE60122516T2 (de) 2007-01-04

Family

ID=22795013

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60122516T Expired - Lifetime DE60122516T2 (de) 2000-06-22 2001-05-01 Phosphonatderivate eines glykopeptides
DE201112100062 Pending DE122011100062I1 (de) 2000-06-22 2011-11-30 Phosphonatderivate eines glykopeptides.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE201112100062 Pending DE122011100062I1 (de) 2000-06-22 2011-11-30 Phosphonatderivate eines glykopeptides.

Country Status (36)

Country Link
US (10) US6635618B2 (de)
EP (1) EP1292612B1 (de)
JP (2) JP3900491B2 (de)
KR (1) KR100768488B1 (de)
CN (1) CN100469788C (de)
AR (1) AR035333A1 (de)
AT (1) ATE337334T1 (de)
AU (2) AU2001261107B2 (de)
BR (1) BRPI0111222B8 (de)
CA (2) CA2713965A1 (de)
CY (2) CY1105194T1 (de)
CZ (1) CZ303672B6 (de)
DE (2) DE60122516T2 (de)
DK (1) DK1292612T3 (de)
EA (1) EA005953B1 (de)
EG (1) EG26726A (de)
ES (1) ES2271012T3 (de)
HK (1) HK1052191B (de)
HR (1) HRP20020888B1 (de)
HU (2) HU229370B1 (de)
IL (1) IL152408A (de)
IS (1) IS2303B (de)
LU (1) LU91908I2 (de)
MX (1) MXPA02012745A (de)
MY (1) MY127081A (de)
NO (2) NO330360B1 (de)
NZ (1) NZ522279A (de)
PL (1) PL207101B1 (de)
PT (1) PT1292612E (de)
RS (1) RS50499B (de)
SI (1) SI1292612T1 (de)
SK (1) SK287470B6 (de)
TW (1) TWI305209B (de)
UA (1) UA75083C2 (de)
WO (1) WO2001098328A2 (de)
ZA (1) ZA200209419B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140993B1 (de) * 1998-12-23 2003-06-11 Theravance, Inc. Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
WO2001083520A2 (en) 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
EP1278549B1 (de) * 2000-05-02 2008-12-10 Theravance, Inc. Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
AU2001259816A1 (en) 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
ES2302733T3 (es) 2000-06-22 2008-08-01 Theravance, Inc. Derivados carboxi-sacaridos de glucopeptido.
TWI312785B (en) * 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
TWI275594B (en) * 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives
ATE556088T1 (de) * 2002-05-24 2012-05-15 Theravance Inc Konjugat beinhaltend cephalosporin und glykopeptidantibiotikum
US6951963B2 (en) 2002-06-17 2005-10-04 Theravance, Inc. Process for preparing N-protected β-amino aldehyde compounds
JP2006528704A (ja) * 2003-05-27 2006-12-21 セラヴァンス インコーポレーテッド グリコペプチド抗細菌剤と組み合わせたポリエンマクロライド抗真菌剤の使用
ES2298821T3 (es) * 2003-07-22 2008-05-16 Theravance, Inc. Utilizacion de un agente antifungico de equinocandina en combinacion con un agente antibacteriano glicopeptidico.
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
AU2007204755A1 (en) * 2006-01-10 2007-07-19 Eugene J. Van Scott N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
JP2008112847A (ja) * 2006-10-30 2008-05-15 Shin Etsu Chem Co Ltd 単結晶シリコン太陽電池の製造方法及び単結晶シリコン太陽電池
WO2008077241A1 (en) 2006-12-22 2008-07-03 Targanta Therapeutics, Inc. Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections
US20090069219A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched telavancin
ES2733353T3 (es) 2007-11-09 2019-11-28 Basf As Compuestos lípidos para uso en productos cosméticos, como suplemento alimenticio o como un medicamento
CA2710602A1 (en) * 2007-12-26 2009-07-09 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
EP2147910A1 (de) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Neue Lipid-Verbindungen
WO2010048340A2 (en) * 2008-10-24 2010-04-29 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
WO2010129233A2 (en) 2009-04-28 2010-11-11 Targanta Therapeutics Corp. Methods of treating bacterial infections using oritavancin
MX2011011614A (es) 2009-05-08 2011-11-18 Pronova Biopharma Norge As Acidos grasos poliinsaturados para el tratamiento de trastornos relacionados a las areas de los trastornos cardiovasculares, metabolicos e inflamatorios.
US20110009596A1 (en) * 2009-07-09 2011-01-13 Plus Chemicals Sa Process for the preparation of n-protected-decylaminoethanal
CA2816949C (en) 2010-11-05 2017-07-04 Pronova Biopharma Norge As Methods of treatment using lipid compounds
WO2013034675A1 (en) 2011-09-09 2013-03-14 Sandoz Ag Process for the synthesis of telavancin and its pharmaceutically acceptable salts as well as n-protected derivatives thereof
EP2753637A1 (de) 2011-09-09 2014-07-16 Sandoz AG Verfahren zur synthese von telavancin, seine pharmazeutisch akzeptablen salze sowie ein n-geschütztes iminderivat von telavancin
JP5724937B2 (ja) * 2012-04-23 2015-05-27 ニプロ株式会社 腎臓集積性を示すペプチド、製剤
CN103897040B (zh) * 2012-12-27 2018-05-22 浙江医药股份有限公司新昌制药厂 新型糖肽类化合物或其药用盐及其制备方法、以及药物组合物和用途
KR102213143B1 (ko) 2013-02-28 2021-02-08 바스프 에이에스 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법
CN105085636B (zh) * 2014-05-19 2020-05-01 中国医学科学院药物研究所 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用
EP3261658B8 (de) 2015-02-23 2019-06-05 Cumberland Pharmaceuticals Inc. Dosen und verfahren zur verabreichung von telavancin
WO2016173923A1 (en) 2015-04-28 2016-11-03 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
CN106188243B (zh) * 2015-05-05 2020-06-26 博瑞生物医药（苏州）股份有限公司 一种奥利万星的制备方法
US20200171124A1 (en) 2016-04-15 2020-06-04 Lupin Limited Topical compositions for ophthalmic and otic use
CN109069580A (zh) * 2016-05-09 2018-12-21 埃克斯利亚制药有限公司 稳定化的糖肽抗生素配制品
AU2018273887B2 (en) 2017-05-22 2022-09-08 Insmed Incorporated Lipo-glycopeptide cleavable derivatives and uses thereof
CN107629115B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107629116B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107987131B (zh) * 2017-11-16 2021-03-09 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的化合物、其制备方法和应用
RU2020122008A (ru) 2017-12-06 2022-01-10 Басф Ас Структурно усиленные жирные кислоты, содержащие кислород, для лечения неалкогольного стеатогепатита
CN108409837B (zh) * 2018-03-06 2021-09-24 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用
US20220024980A1 (en) * 2018-11-21 2022-01-27 Insmed Incorporated Lipo-glycopeptide cleavable derivatives and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872A (en) * 1849-11-13 Means of changing the combination in bevolving tumbler-locks
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
US4885275A (en) * 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
CA2031803C (en) 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US5217493A (en) * 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
CA2150554A1 (en) 1992-12-02 1994-06-09 Sheng-Wan Tsao Cyclodextrin and polymer based drug delivery system
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
MY128335A (en) 1994-01-28 2007-01-31 Lilly Co Eli Glycopeptide antibiotic derivatives
US5614615A (en) 1995-03-21 1997-03-25 The Scripps Research Institute Sialyl Lewis X mimetics incorporating fucopeptides
US5919756A (en) 1996-06-28 1999-07-06 Eli Lilly And Company Amides
WO1999017793A1 (fr) * 1997-10-03 1999-04-15 Fujisawa Pharmaceutical Co., Ltd. Chlorhydrates de vancomycines antibiotiques et leur procede de production
US5916873A (en) 1997-04-17 1999-06-29 Eli Lilly And Company Teicoplanin derivatives
US6323176B1 (en) * 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
WO2000004044A1 (en) * 1998-07-14 2000-01-27 Princeton University Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same
EP1140993B1 (de) * 1998-12-23 2003-06-11 Theravance, Inc. Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
DE19911097A1 (de) 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
EP1173193A4 (de) 1999-04-02 2003-01-29 Univ Princeton Des-leucyl glykopeptidantibiotika und methoden zu deren herstellung
JP2000302687A (ja) 1999-04-22 2000-10-31 Sagami Chem Res Center 抗菌性オリゴマー及び抗菌剤
WO2001083520A2 (en) 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
EP1278549B1 (de) 2000-05-02 2008-12-10 Theravance, Inc. Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
ATE510533T1 (de) 2000-06-21 2011-06-15 Cubist Pharm Inc Arzneizusammensetzungen und verfahren zum verbessern der oralen absorption von antimikrobiellen wirkstoffen
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
ES2302733T3 (es) 2000-06-22 2008-08-01 Theravance, Inc. Derivados carboxi-sacaridos de glucopeptido.
WO2001098326A2 (en) 2000-06-22 2001-12-27 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
AU2001259816A1 (en) 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives
TWI275594B (en) * 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives

Also Published As

Publication number Publication date
NO2011025I1 (no) 2011-11-18
US6887976B2 (en) 2005-05-03
CA2411590C (en) 2010-10-19
BRPI0111222B8 (pt) 2021-05-25
DK1292612T3 (da) 2007-01-02
WO2001098328A3 (en) 2002-04-11
MY127081A (en) 2006-11-30
HUS1400024I1 (hu) 2017-03-28
ATE337334T1 (de) 2006-09-15
KR20030032970A (ko) 2003-04-26
US7700550B2 (en) 2010-04-20
AU6110701A (en) 2002-01-02
BRPI0111222B1 (pt) 2015-03-17
US20120283195A1 (en) 2012-11-08
US6635618B2 (en) 2003-10-21
US8541375B2 (en) 2013-09-24
US7008923B2 (en) 2006-03-07
JP3900491B2 (ja) 2007-04-04
PL359419A1 (en) 2004-08-23
NO20025954L (no) 2002-12-11
TWI305209B (en) 2009-01-11
US20030207797A1 (en) 2003-11-06
CN1437611A (zh) 2003-08-20
US20100160211A1 (en) 2010-06-24
DE122011100062I1 (de) 2012-03-15
US20040063916A1 (en) 2004-04-01
SI1292612T1 (sl) 2006-12-31
US7351691B2 (en) 2008-04-01
WO2001098328A2 (en) 2001-12-27
PL207101B1 (pl) 2010-11-30
NZ522279A (en) 2004-07-30
HUP0301320A2 (hu) 2003-08-28
US20060063706A1 (en) 2006-03-23
EA005953B1 (ru) 2005-08-25
US20020022590A1 (en) 2002-02-21
CA2411590A1 (en) 2001-12-27
HU229370B1 (hu) 2013-11-28
PT1292612E (pt) 2006-12-29
US20080312407A1 (en) 2008-12-18
DE60122516T2 (de) 2007-01-04
NO20025954D0 (no) 2002-12-11
ES2271012T3 (es) 2007-04-16
CN100469788C (zh) 2009-03-18
US20050164916A1 (en) 2005-07-28
AR035333A1 (es) 2004-05-12
EP1292612A2 (de) 2003-03-19
UA75083C2 (uk) 2006-03-15
SK287470B6 (sk) 2010-10-07
CY1105194T1 (el) 2010-03-03
CZ303672B6 (cs) 2013-02-20
CZ20023942A3 (cs) 2003-03-12
US8859506B2 (en) 2014-10-14
HRP20020888A2 (en) 2005-02-28
BR0111222A (pt) 2003-04-01
IS6600A (is) 2002-10-29
JP2004501161A (ja) 2004-01-15
EG26726A (en) 2014-06-18
US7208471B2 (en) 2007-04-24
MXPA02012745A (es) 2004-04-05
CA2713965A1 (en) 2001-12-27
KR100768488B1 (ko) 2007-10-18
JP2007045842A (ja) 2007-02-22
LU91908I2 (fr) 2012-01-30
CY2012006I1 (el) 2016-06-22
HK1052191A1 (en) 2003-09-05
IL152408A (en) 2009-05-04
EA200300050A1 (ru) 2003-04-24
NO2011025I2 (de) 2011-11-18
CY2012006I2 (el) 2016-06-22
EP1292612B1 (de) 2006-08-23
HK1052191B (zh) 2007-01-26
NO330360B1 (no) 2011-04-04
YU96902A (sh) 2006-01-16
US6872701B2 (en) 2005-03-29
IL152408A0 (en) 2003-05-29
HUP0301320A3 (en) 2007-05-29
IS2303B (is) 2007-10-15
US8101575B2 (en) 2012-01-24
RS50499B (sr) 2010-03-02
ZA200209419B (en) 2004-02-19
HRP20020888B1 (en) 2007-12-31
AU2001261107B2 (en) 2006-07-20
US20140024604A1 (en) 2014-01-23
US20070049519A1 (en) 2007-03-01
SK18522002A3 (sk) 2003-06-03

Similar Documents

Publication Publication Date Title
DE60122516D1 (de) Phosphonatderivate eines glykopeptides
NO20025978D0 (no) Benzotiazol-derivater
IS6668A (is) Kolkínólafleiður sem æðamyndunarhemlar
ATE271031T1 (de) Neue phenylpropargyletherderivate
DK1292604T3 (da) 2-Aminocarbonyl-9H-purinderivater
DE60121457D1 (de) Regelung eines turboladers
ATE298332T1 (de) Decahydro-isochinolinderivate
DK1280809T3 (da) Antitumorecteinascidinderivater
DE60122181D1 (de) Regelung eines turboladers
ATE332895T1 (de) Tetrazolderivate
DE60111268D1 (de) Neue pleuromutilinderivate
DK1322593T3 (da) O-substituerede-6-methyl-tramadol-derivater
ATE265422T1 (de) Neue phenylheteroalkylamin-derivate
DE60038610D1 (de) Neue kristalline formen eines macrolidantibiotikums
DE50208357D1 (de) Ansteuerung eines leuchtrings
ATE280752T1 (de) Aminomethyl-phenyl-cyclohexanonderivate
ATE366244T1 (de) Tetrazolderivate
EE200300116A (et) Efektiivne meetod faktori Xa inhibiitori valmistamiseks
DE60133746D1 (de) Tartratsalze eines thiazolidinedione derivats
DE69915044D1 (de) Verriegelbare Betätigungseinheit eines Ventils
DE50107843D1 (de) Fronteinheit eines gerätes
DE60132461D1 (de) Tartratsalze eines thiazolidinedione derivats
DE50008654D1 (de) Positionsbestimmung eines Bauteils
DE60119863D1 (de) Regelung eines Turboladers
ATE374776T1 (de) Pyrrolotriazolopyrimidinonderivate